# Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer

**Authors:** Meng Liu, Maria O. Hernandez, Darko Castven, Hsin-Pei Lee, Wenqi Wu, Limin Wang, Marshonna Forgues, Jonathan M. Hernandez, Jens U. Marquardt, Lichun Ma

PMC · DOI: 10.1038/s41467-026-69797-z · Nature Communications · 2026-02-21

## TL;DR

The study reveals how tumor cells and their surroundings form distinct clusters, or 'villages,' in liver cancer, which are linked to patient outcomes.

## Contribution

The novel concept of tumor cell villages and their specific molecular co-dependencies with the microenvironment is introduced.

## Key findings

- Tumor cell states are organized into distinct spatial clusters called 'villages' supported by unique microenvironments.
- Perturbing the microenvironment disrupts tumor cell villages and their stability.
- Village-specific molecular co-dependencies correlate with patient outcomes in liver cancer.

## Abstract

Spatial cellular context is crucial in shaping intratumor heterogeneity. However, understanding how each tumor establishes its unique spatial landscape and what factors drive the landscape for tumor fitness remains significantly challenging. Here, we analyze over 2 million cells from 50 tumor biospecimens using spatial single-cell imaging and single-cell RNA sequencing. We develop a deep learning-based strategy to spatially map tumor cell states and their surrounding environmental architecture, and find that different tumor cell states can be organized into distinct clusters, or “villages,” each supported by unique microenvironments. Notably, tumor cell villages exhibit village-specific molecular co-dependencies between tumor cells and their microenvironment and are associated with patient outcomes. Perturbation of molecular co-dependencies via random spatial shuffling of the microenvironment results in destabilization of the corresponding villages. We validate our findings using single-cell, spatial, and bulk transcriptome data from 740 liver cancer patients. This study provides insights into understanding tumor spatial landscape and its impact on tumor aggressiveness.

Understanding how each tumor establishes its unique spatial landscape and what factors drive the landscape for tumor fitness remains significantly challenging. Here, the authors employ spatial single-cell imaging and single-cell RNA sequencing to analyze 50 liver cancer biospecimens and find that different tumor cell states may be organized into distinct clusters, or ‘villages’.

## Linked entities

- **Diseases:** liver cancer (MONDO:0002691)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Spink1 (serine peptidase inhibitor, Kazal type 1) [NCBI Gene 20730] {aka Spink3, p12}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, SPINK1 (serine peptidase inhibitor Kazal type 1) [NCBI Gene 6690] {aka PCTT, PSTI, Spink3, TATI, TCP}, IGFBP7 (insulin like growth factor binding protein 7) [NCBI Gene 3490] {aka AGM, FSTL2, IBP-7, IGFBP-7, IGFBP-7v, IGFBPRP1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, COL5A1 (collagen type V alpha 1 chain) [NCBI Gene 1289] {aka EDSC, EDSCL1, FMDMF}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TUBB (tubulin beta class I) [NCBI Gene 203068] {aka CDCBM6, CSCSC1, M40, OK/SW-cl.56, TUBB1, TUBB5}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, HSPG2 (heparan sulfate proteoglycan 2) [NCBI Gene 3339] {aka HSPG, PLC, PRCAN, SJA, SJS, SJS1}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, ATP1B3 (ATPase Na+/K+ transporting subunit beta 3) [NCBI Gene 483] {aka ATPB-3, CD298}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, VIM (vimentin) [NCBI Gene 7431], CXCL5 (C-X-C motif chemokine ligand 5) [NCBI Gene 6374] {aka ENA-78, SCYB5}, BGN (biglycan) [NCBI Gene 633] {aka DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, COL4A1 (collagen type IV alpha 1 chain) [NCBI Gene 1282] {aka BSVD, BSVD1, COL4A1s, PADMAL, RATOR}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, TPT1 (tumor protein, translationally-controlled 1) [NCBI Gene 7178] {aka HRF, TCTP, p02, p23}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, ATF7IP (activating transcription factor 7 interacting protein) [NCBI Gene 55729] {aka AM, ATF-IP, ATF7IP1, MCAF, MCAF1, p621}, CD74 (CD74 molecule) [NCBI Gene 972] {aka CLIP, DHLAG, HLADG, II, Ia-GAMMA, p33}, IGKC (immunoglobulin kappa constant) [NCBI Gene 3514] {aka HCAK1, IGKCD, Km}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, Col1a1 (collagen, type I, alpha 1) [NCBI Gene 12842] {aka Col1a-1, Cola-1, Cola1, Mov-13, Mov13}, KRT17 (keratin 17) [NCBI Gene 3872] {aka 39.1, CK-17, K17, PC2, PCHC1}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, IL32 (interleukin 32) [NCBI Gene 9235] {aka IL-32alpha, IL-32beta, IL-32delta, IL-32gamma, NK4, TAIF}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, ISG20 (interferon stimulated exonuclease gene 20) [NCBI Gene 3669] {aka CD25, HEM45}, DCC (DCC netrin 1 receptor) [NCBI Gene 1630] {aka CRC18, CRCR1, HGPPS2, IGDCC1, MRMV1, NTN1R1}, LUM (lumican) [NCBI Gene 4060] {aka LDC, SLRR2D}, MGP (matrix Gla protein) [NCBI Gene 4256] {aka GIG36, MGLAP, NTI}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, RGS5 (regulator of G protein signaling 5) [NCBI Gene 8490] {aka MST092, MST106, MST129, MSTP032, MSTP092, MSTP106}, B2M (beta-2-microglobulin) [NCBI Gene 414830] {aka b2m-W01, b2m-W03, b2m-Z01, b2m-Z02, b2m-Z03}
- **Diseases:** metastasis (MESH:D009362), inflammatory (MESH:D007249), Malignant (MESH:D009369), infections (MESH:D007239), vascularized (MESH:D057772), iCCA (MESH:D018281), ovarian cancer (MESH:D010051), HCC (MESH:D006528), CCA (MESH:C536211), liver tumor (MESH:D008113), SDN (MESH:D008569)
- **Chemicals:** bile acid (MESH:D001647), paraffin (MESH:D010232), Alexa 488 (-), Metal (MESH:D008670), NaP (MESH:C043186), formamide (MESH:C031066), DEPC (MESH:D004047), Xylene (MESH:D014992), fatty acid (MESH:D005227), water (MESH:D014867), Tris-glycine (MESH:C035647), lipid (MESH:D008055), PBS (MESH:D007854), Tween (MESH:D011136), reactive oxygen species (MESH:D017382), glycine (MESH:D005998), DAPI (MESH:C007293), ethanol (MESH:D000431), Formalin (MESH:D005557)
- **Species:** Human immunodeficiency virus (species) [taxon 12721], hepatitis C virus [taxon 11103], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** SDN — Mus musculus (Mouse), Embryonic stem cell (CVCL_IU77)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932787/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932787/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932787/full.md

---
Source: https://tomesphere.com/paper/PMC12932787